Marketed Products

Through a license agreement with Forest Laboratories (a wholly owned subsidiary of Allergan plc), the Adamas portfolio includes two drugs commercially available in the United States: NAMENDA XR® (memantine hydrochloride) extended-release capsules and NAMZARIC® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules.

NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.

About NAMENDA XR® and NAMZARIC®

Through a license agreement with Allergan, the Adamas portfolio includes two drugs commercially available in the United States: NAMENDA XR (memantine hydrochloride) extended-release capsules and NAMZARIC (memantine hydrochloride extended-release and donepezil hydrochloride) capsules.

NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Donepezil is the active ingredient in ARICEPT® (donepezil hydrochloride), which is indicated for the treatment of mild to severe dementia of the Alzheimer’s type. NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.

Allergan owns the exclusive U.S. commercialization rights to both medicines, while Adamas has the right to develop a version of both medicines in ex-U.S. markets. Adamas is eligible to receive royalties from Allergan for U.S. sales of NAMENDA XR and NAMZARIC beginning in June 2018 and May 2020, respectively.

Eligible to receive royalties on U.S. sales of NAMENDA XR® and NAMZARIC® beginning in 2018 and 2020, respectively.